N A Farid - JoVE Visualize

Showing results (11-20 of 24) with videos related to

Pageof 3

Sort By:

Clinical Chemistry|July 1, 1975

Improved colorimetric determination of salicylic acid and its metabolites in urineN A Farid, G S Born, W V Kessler, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 1, 1996

Stereoselective disposition of the enantiomers of the benzoquinolinone LY191704, a human type I 5 alpha-reductase inhibitor. Differences between rats and dogsN A Farid, K M Schreiner, N L Coleman, et al.

The Journal of Clinical Psychiatry|March 1, 1985

Fluoxetine: clinical pharmacology and physiologic dispositionL Lemberger, R F Bergstrom, R L Wolen, et al.

Xenobiotica; the Fate of Foreign Compounds in Biological Systems|July 11, 2007

Absorption, distribution and excretion of the new thienopyridine agent prasugrel in ratsK Hagihara, A Kurihara, K Kawai, et al.

Journal of Pharmaceutical Sciences|April 1, 1977

Synthesis of 14C-meglumine salicylate and its disposition in humans after oral administrationN A Farid, G S Born, W V Kessler, et al.

Journal of Pharmaceutical and Biomedical Analysis|January 1, 1989

Liquid chromatographic control of the identity, purity and "potency" of biomolecules used as drugsN A Farid, L M Atkins, G W Becker, et al.

Xenobiotica; the Fate of Foreign Compounds in Biological Systems|March 13, 2009

Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogsK Hagihara, M Kazui, H Ikenaga, et al.

Pharmaceutical Research|January 6, 2001

Confidence interval criteria for assessment of dose proportionalityB P Smith, F R Vandenhende, K A DeSante, et al.

Journal of Clinical Pharmacy and Therapeutics|September 12, 2009

Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver diseaseD S Small, N A Farid, Y G Li, et al.

Clinical Pharmacology and Therapeutics|March 16, 2007

Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differentlyN A Farid, C D Payne, D S Small, et al.

Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:

Pageof 3

Clinical Chemistry|July 1, 1975

Improved colorimetric determination of salicylic acid and its metabolites in urineN A Farid, G S Born, W V Kessler, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 1, 1996

Stereoselective disposition of the enantiomers of the benzoquinolinone LY191704, a human type I 5 alpha-reductase inhibitor. Differences between rats and dogsN A Farid, K M Schreiner, N L Coleman, et al.

The Journal of Clinical Psychiatry|March 1, 1985

Fluoxetine: clinical pharmacology and physiologic dispositionL Lemberger, R F Bergstrom, R L Wolen, et al.

Xenobiotica; the Fate of Foreign Compounds in Biological Systems|July 11, 2007

Absorption, distribution and excretion of the new thienopyridine agent prasugrel in ratsK Hagihara, A Kurihara, K Kawai, et al.

Journal of Pharmaceutical Sciences|April 1, 1977

Synthesis of 14C-meglumine salicylate and its disposition in humans after oral administrationN A Farid, G S Born, W V Kessler, et al.

Journal of Pharmaceutical and Biomedical Analysis|January 1, 1989

Liquid chromatographic control of the identity, purity and "potency" of biomolecules used as drugsN A Farid, L M Atkins, G W Becker, et al.

Xenobiotica; the Fate of Foreign Compounds in Biological Systems|March 13, 2009

Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogsK Hagihara, M Kazui, H Ikenaga, et al.

Pharmaceutical Research|January 6, 2001

Confidence interval criteria for assessment of dose proportionalityB P Smith, F R Vandenhende, K A DeSante, et al.

Journal of Clinical Pharmacy and Therapeutics|September 12, 2009

Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver diseaseD S Small, N A Farid, Y G Li, et al.

Clinical Pharmacology and Therapeutics|March 16, 2007

Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differentlyN A Farid, C D Payne, D S Small, et al.

Pageof 3